Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors

Core Viewpoint - Corcept Therapeutics is facing a class action lawsuit due to alleged misrepresentations regarding the approval process of its drug relacorilant, which has led to significant stock price declines following negative FDA feedback [4][5][6]. Group 1: Class Action Details - The class action is on behalf of investors who purchased Corcept securities between October 31, 2024, and December 31, 2025, with a deadline for filing a lead plaintiff motion set for April 21, 2026 [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Group 2: Company Overview - Corcept Therapeutics specializes in the discovery and development of medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders, with relacorilant being a key product candidate for treating hypercortisolism [3]. Group 3: Allegations Against Corcept - The lawsuit claims that Corcept misled investors by stating that the relacorilant New Drug Application (NDA) was well-supported and nearing approval, despite known concerns from the FDA regarding clinical evidence [4]. - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) indicating that additional evidence was needed for a favorable benefit-risk assessment, resulting in a stock price drop of over 50% [5]. - A redacted copy of the CRL published by the FDA on January 30, 2026, highlighted concerns about the adequacy of clinical studies submitted, and prior warnings from the FDA about potential review issues were noted [6].